Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316)
Journal of Clinical Oncology · 20.11.2026
DOI: 10.1200/jco-26-00854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 20.11.2026. Verfasst von Alessandro Leonetti und 22 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Purpose
Stage III non–small cell lung cancer (NSCLC) is a heterogeneous disease with no single definitive therapeutic approach. The role of neoadjuvant tyrosine kinase inhibitors in stage III ALK-positive NSCLC remains unknown. The ALNEO study evaluated the activity and safety of perioperative alectinib in this population. Patients and Methods ALNEO is an open-label, single-arm, multicenter phase II study enrolling treatment-naïve patients with potentially resectable stage III ALK-positive NSCLC. Patients received neoadjuvant alectinib 600 mg twice daily for 8 weeks, followed by surgery and adjuvant alectinib for up to 96 weeks. The primary end point was major pathologic response (MPR; ≤10% residual viable tumor cells) assessed by blinded independent central review. Secondary end points included pathologic complete response (pCR), objective response rate (ORR), event-free survival (EFS), disease-free survival (DFS), overall survival (OS), and safety.
Results
From May 2021 to July 2024, 33 patients were enrolled. The median age was 62 years (range, 33-79), 70% were female, and 52% were never smokers. Clinical stage was IIIA in 64% and IIIB in 36%. All patients completed neoadjuvant treatment, and 28 (85%) underwent surgery, most commonly lobectomy (75%). R0 resection was achieved in 24 (86%). MPR was observed in 14 patients (42%; 95% CI, 26 to 61), including four pCRs (12%; 95% CI, 3 to 28). ORR was 67%. Adjuvant treatment was initiated in 26 (79%) patients. After a median follow-up of 26.8 months, median EFS, DFS, and OS were not reached; six patients (18%) experienced disease recurrence. Grade ≥3 adverse events occurred in 9% and 27% of patients during neoadjuvant and adjuvant treatment, respectively.
Conclusion
The ALNEO study met its primary end point, suggesting perioperative alectinib as a feasible and active approach in potentially resectable stage III ALK-positive NSCLC.
Zitieren
APA
Leonetti, A., Boni, L., Gnetti, L., D'Agnelli, S., Cortinovis, D. L., Pasello, G., Gelsomino, F., Mazzoni, F., Bearz, A., Metro, G., Cecere, F. L., Passiglia, F., Belluomini, L., Delmonte, A., Ricciardi, S., Bria, E., Bertolini, F., Toschi, L., Parra, H. S., …, & Tiseo, M. (2026). Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316). Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00854
Vancouver
Leonetti A, Boni L, Gnetti L, D'Agnelli S, Cortinovis DL, Pasello G, et al. Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316). Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00854
BibTeX
@article{Leonetti2026,
author = {Leonetti, Alessandro and Boni, Luca and Gnetti, Letizia and D'Agnelli, Simona and Cortinovis, Diego Luigi and Pasello, Giulia and Gelsomino, Francesco and Mazzoni, Francesca and Bearz, Alessandra and Metro, Giulio and Cecere, Fabiana Letizia and Passiglia, Francesco and Belluomini, Lorenzo and Delmonte, Angelo and Ricciardi, Serena and Bria, Emilio and Bertolini, Federica and Toschi, Luca and Parra, Hector Soto and Treccani, Mirko and Minari, Roberta and Tognetto, Michele and Tiseo, Marcello},
title = {Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316)},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00854}
}
EUVIMED